The sponsor of a Phase III Follicular Lymphoma trial needed a data-led approach to optimize protocol design and identify highest enrolling sites. Competition for patients was very high.


Phesi’s Trial Accelerator™ platform, driven by the world’s largest trial database, was used to:

  • Analyze and optimize key protocol design elements
  • Assess the operational impact from key protocol design elements on enrollment cycle time, country and investigator site selection
  • Identify top enrolling investigator sites
  • Critically appraise investigator site recommendations from two leading CROs
  • Conduct a competitor trial analysis

Phesi also recommended that the study team:

  • Activate a total of 185 sites to enroll 528 patients in 31 months
  • Use a two-batch approach to achieve a target site activation performance of >64%
  • Activate 120 sites first and use recruitment modeling (including peak performance analysis) to establish when to activate new sites to deliver the shortest cycle time



Phesi’s approach supported internal decision making and was used to guide discussions on reducing patient and investigator site burden, cost and trial duration.



Request a demo and find out how Phesi can help
you achieve smarter trials and faster cures




Related cases
03. 14. 2023
Protocol Design and Investigator Site Selection: Type 2 Diabetes Mellitus (T2DM) Read more
03. 14. 2023
Protocol Design, Country and Investigator Site Selection: NSCLC Read more
03. 14. 2023
Protocol Optimization and Study Feasibility: Iron Overload Integrated Development Plan, Phase 1B Trial Read more
03. 14. 2023
Protocol Planning: Inotuzumab Ozogamicin In Acute Lymphoblastic Leukemia (ALL) Read more
03. 14. 2023
Protocol Design and Investigator Site Selection: Phase III Osteoarthritis Pain of the Knee Trial Read more